

Mexico City, March 23, 2018

## GENOMMA LAB INTERNACIONAL SUCCESSFULLY ISSUES LAB 18 LOCAL BOND FOR \$2.45 BILLION PESOS

*Genomma Lab Internacional, S.A.B. de C.V.* (BMV: LAB b) (“Genomma Lab” or “the Company”), Mexican company focused on the pharmaceutical and personal care products industry with presence in 19 countries, announces that it successfully completed the issuance of local bonds for 2.45 billion pesos in the Mexican Securities Market. The transaction was allocated among a diversified investor base.

The debt certificates issued were rated “AA(mex)” for debt in local currency by Fitch Ratings and “HR AA” by HR Ratings. The details of the issuance are:

CONCEPT	LAB 18
Amount (MXN\$)	\$2.45 billion
Maturity	March 19, 2021 (3 years)
Interest Rate	TIEE 28 days + 190 bps
Payment of Capital	Bullet
Payment of Interests	Every 28 days

The proceeds will be used to refinance debt. This will improve the Company’s maturity debt profile and optimize the average life of liabilities.

Antonio Zamora, Chief Financial Officer commented: *“The successful issuance of LAB 18 reaffirms the market trust in Genomma Lab. These proceeds will improve our financial position allowing us to invest in projects with high returns and generate greater value for our shareholders”.*

### About the Company

---

*Genomma Lab Internacional, S.A.B. de C.V.* is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low-cost, highly flexible supply chain operating model. For more information visit: [www.genommalab.com](http://www.genommalab.com)

Genomma Lab trades on the Mexican Stock Exchange under the ticker symbol “LAB B”

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.